February 2023

Informal Care

Informal care is generally thought to mean unpaid care, typically provided to elderly and dependent persons by those they have a social relationship with. Such as a spouse, parent, child or other relative. As well as maybe a neighbour or close friend.
Read More
January 2023

Innovative evidence methods and their practical application in improving patient’s lives A review of 2022 news content published by the Prime Global evidence specialist - HCD Economics

Our news coverage in 2022, has focused on our commitment to generating evidence to inform decisions that deliver health equity. Our news reports share methodologies and results from our innovative research programme covering a wide range of disease areas and applied health economic analytical techniques.
Read More
December 2022

Preference Research in Rare Disease

Approximately 6,000–7,000 of the 30,000 known diseases could be defined as rare or orphan diseases with a prevalence threshold of around 40-50 cases per 100,000 people. Meaning the total global prevalence of rare disease is around 5%, or 400 million people worldwide. With over 30 million rare disease sufferers living in the EU and 25 million from the US.
Read More
September 2022

BMS supports patient preference study – continuing research investment for the beta-thalassemia community

HCD Economics has championed the application of Time Trade Off (TTO) methodology, to the research objective of expanding the health economic evidence for treatments that improve the life of patients. A number of TTO studies are underway and in the March 22nd edition of the prestigious European Journal of Health Economics (impact factor 3.689 [2020] - 472,118 downloads (2021), the TTO study undertaken by HCD Economics was published and is available now as an open access publication. (https://link.springer.com/article/10.1007/s10198-022-01449-7).
Read More
July 2022

A Real World Leader for every patient in Europe

The European Medicines Agency (EMA), which serves a population of 500 million citizens, has the stated remit of promoting and protecting public health in European Union (EU) member states, as well as the countries in the European Economic Area, by ensuring all medicines available on the EU market are safe, effective and of high quality.
Read More